SSB
ALXN

Sandy Spring Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Sandy Spring Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14
Closed -$2K – 1065
2020
Q4 		$2K Buy
+14
New +$1.8K ﹤0.01% 914
2019
Q3 		– Sell
-66
Closed -$9K – 882
2019
Q2 		$9K Buy
66
+28
+74% +$3.61K ﹤0.01% 734
2019
Q1 		$5K Buy
+38
New +$4.72K ﹤0.01% 727
2017
Q2 		– Sell
-19
Closed -$2K – 877
2017
Q1 		$2K Sell
19
-19
-50% -$2.45K ﹤0.01% 811
2016
Q4 		$4K Buy
38
+19
+100% +$2.33K ﹤0.01% 769
2016
Q3 		$2K Hold
19
– – ﹤0.01% 810
2016
Q2 		$2K Hold
19
– – ﹤0.01% 866
2016
Q1 		$3K Hold
19
– – ﹤0.01% 869
2015
Q4 		$4K Buy
+19
New +$3.32K ﹤0.01% 813
2014
Q4 		– Sell
-100
Closed -$17K – 828
2014
Q3 		$17K Hold
100
– – ﹤0.01% 566
2014
Q2 		$16K Sell
100
-25
-20% -$3.95K ﹤0.01% 562
2014
Q1 		$19K Buy
+125
New +$19.9K ﹤0.01% 498

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sandy Spring Bank's ALXN Position: Q1 2021 in Review

Sandy Spring Bank sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 14 shares — an estimated $2K sold.

Sandy Spring Bank first reported a position in ALXN in Q1 2014 and held it in 12 quarters. The position peaked at $19K in Q1 2014. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Sandy Spring Bank reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Sandy Spring Bank sold 14 Alexion Pharmaceuticals shares in Q1 2021, an estimated $2K.
  • Sandy Spring Bank first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 12 quarters.
  • Sandy Spring Bank's Alexion Pharmaceuticals position peaked at $19K in Q1 2014.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Sandy Spring Bank's 13F filing for Q1 2021, filed 3 May 2021.